The Netherlands is home to a vibrant, concentrated Life Sciences Health cluster of more than 2200 life science and medtech companies and research organisations, all within a 120-mile radius. Holland is the most geographically concentrated region in the world when it comes to creating economic and social value in Life Sciences and Health. Expertise in healthcare infrastructure is characterised by a turnkey plus approach: Dutch companies are able to cover all aspects from hospital design & engineering, financing, waste management, medical equipment etc. while paying special attention to energy efficiency and healing environments. The excellent medical research infrastructure is strongly focused on translational research in the different medical fields such as oncology, cardiovascular and immunology. The Netherlands is a global market leader in mobile healthcare, which enables the Dutch to contribute to rural healthcare in developing countries around the globe. The Netherlands has an excellent research and innovation portfolio in a number of niches, such as vaccination, antibiotic resistance and polio. The Netherlands is consistently ranked in the top three of the EuroHealth Consumer Index. Dutch Healthcare ranks number one among 35 countries, above Switzerland, Iceland, Denmark and Norway.

The Netherlands ranks 8th worldwide in life sciences and health patents. The Netherlands ranks 6th in the world in life sciences and health citations. 70% of Dutch LSH companies (in numbers) are commercially active abroad. More than 50% of the Dutch LSH companies (in numbers) cooperate with non-Dutch companies or knowledge institutions. Five of the top-10 biotech deals within the European Union in the last 4 years involved Dutch companies. Within the European Commission’s R&D Programme 49% of initiatives in the health cluster involve Dutch participants (total budget of 2.48 billion euros).

The LSH companies supply:

- €6.4 bn. in export of goods (€3.48 bn. pharmacy, €2.87 bn. medical instruments and €58 m. R&D).
- €18.3 bn. in production (divided into: resp. €5.52 bn., €11.8 bn. and €1 bn.).
- €4.58 bn. in added value (divided into: resp. €2.58 bn., €1.71 bn. and €0.29 bn.).
- 35,000 FTEs working in companies.
In the LSH companies themselves €670 m. is spent on their own R&D. In total the LSH companies invest €1.5 bn. in innovation spending (R&D in own company, outsourced R&D, research facilities, etc).

- Turnover: €80 billion

- In 2014 the country had 82 hospitals at 276 locations of which 8 are University Medical Centres and 22 classified as hospitals, 106 private clinics and 213 independent treatment centres. The number of beds was set at 4.7 per 1000, which is well below the OECD average and in further decline.

- In 2011 the average stay in hospitals was 5.8 days. The number of long-term beds was 68.5 per 1000 in 2011. Primarily caused by an ageing population. Hence the Dutch government’s emphasis on elderly care (and homecare).

- In 2014 over 1.1 million people worked in the Dutch Life Sciences and Health sector, including 8865 General Practitioners.

For more information
www.lifescienceshealth.com
www.tfhc.nl
www.nefarma.nl/english/homepage
www.nfu.nl/english/about-the-nfu/
www.vsnu.nl/home-english.html
www.knaw.nl/en?set_language=en
www.government.nl/ministries/vws
www.dutchbiotech.com
www.tfhc.nl
www.hollandbio.nl
www.medischetecnologie.fhi.nl
www.hollandhealthtech.nl/site/

Sources
Figures based on CBS information for the year 2012, unless stated otherwise. Also based on information from the Dutch Ministry of Health, Welfare and Sport, the Dutch Ministry of Economic Affairs, Dutch cluster organisation Life Sciences Health, Task Force Health Care, FME, World Intellectual Property Organisation (WIPO), The Commonwealth Fund.

Information
www.health-holland.com